<?xml version='1.0' encoding='utf-8'?>
<document id="28346018"><sentence text="Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis."><entity charOffset="64-73" id="DDI-PubMed.28346018.s1.e0" text="rifamycin" /></sentence><sentence text="In high prevalence settings, tuberculosis and HIV dual infection and co-treatment is frequent" /><sentence text=" Rifamycins, especially rifampicin, in combination with isoniazid, ethambutol and pyrazinamide are key components of short-course antituberculosis therapy"><entity charOffset="1-11" id="DDI-PubMed.28346018.s3.e0" text="Rifamycins" /><entity charOffset="24-34" id="DDI-PubMed.28346018.s3.e1" text="rifampicin" /><entity charOffset="56-65" id="DDI-PubMed.28346018.s3.e2" text="isoniazid" /><entity charOffset="67-77" id="DDI-PubMed.28346018.s3.e3" text="ethambutol" /><entity charOffset="82-94" id="DDI-PubMed.28346018.s3.e4" text="pyrazinamide" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e0" e2="DDI-PubMed.28346018.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e0" e2="DDI-PubMed.28346018.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e0" e2="DDI-PubMed.28346018.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e0" e2="DDI-PubMed.28346018.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e0" e2="DDI-PubMed.28346018.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e1" e2="DDI-PubMed.28346018.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e1" e2="DDI-PubMed.28346018.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e1" e2="DDI-PubMed.28346018.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e1" e2="DDI-PubMed.28346018.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e2" e2="DDI-PubMed.28346018.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e2" e2="DDI-PubMed.28346018.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e2" e2="DDI-PubMed.28346018.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e3" e2="DDI-PubMed.28346018.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28346018.s3.e3" e2="DDI-PubMed.28346018.s3.e4" /></sentence><sentence text=" Areas covered: We reviewed available data, for which articles were identified by a Pubmed search, on rifamycin-antiretroviral interactions in HIV-infected children"><entity charOffset="102-111" id="DDI-PubMed.28346018.s4.e0" text="rifamycin" /></sentence><sentence text=" Rifamycins have potent inducing effects on phase I and II drug metabolising enzymes and transporters"><entity charOffset="1-11" id="DDI-PubMed.28346018.s5.e0" text="Rifamycins" /></sentence><sentence text=" Antiretroviral medications are often metabolised by the enzymes induced by rifamycins or may suppress specific enzyme activity leading to drug-drug interactions with rifamycins"><entity charOffset="76-86" id="DDI-PubMed.28346018.s6.e0" text="rifamycins" /><entity charOffset="167-177" id="DDI-PubMed.28346018.s6.e1" text="rifamycins" /><pair ddi="false" e1="DDI-PubMed.28346018.s6.e0" e2="DDI-PubMed.28346018.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28346018.s6.e0" e2="DDI-PubMed.28346018.s6.e1" /></sentence><sentence text=" These may cause significant alterations in their phamacokinetic and pharmacodynamic properties, and sometimes that of the rifamycin"><entity charOffset="123-132" id="DDI-PubMed.28346018.s7.e0" text="rifamycin" /></sentence><sentence text=" Recommended strategies to adapt to these interactions include avoidance and dose adjustment" /><sentence text=" Expert opinion: Despite the importance and frequency of tuberculosis as an opportunistic disease in HIV-infected children, current data on the management of co-treated children is based on few studies" /><sentence text=" We need new strategies to rapidly assess the use of rifamycins, new anti-tuberculosis drugs and antiretroviral drugs together as information on safety and dosing of individual drugs becomes available"><entity charOffset="53-63" id="DDI-PubMed.28346018.s10.e0" text="rifamycins" /></sentence><sentence text="" /></document>